TLR4-IN-C34 (C34, 1 mg/kg, orally daily) could attenuate NEC severity and demonstrates a marked preservation of the intestinal mucosa. Animal Model: Experimental NEC induced in 7-8 day old mice. Dosage: 1 mg/kg. Administration: Orally every morning. Result: Attenuated intestinal inflammation.